Abstract
Between 2000 and 2005, 143 consecutive patients received two partially HLA matched UCB units to enhance engraftment. 50 patients [median age: 24 years (range: 11-60 years)] received cyclophosphamide (CY) 120 mg/kg, TBI 1320 cGy and fludarabine 75 mg/m2 with GVHD prophylaxis of cyclosporin (CSA) and mycophenolate (MMF). The median nucleated cell (NC) dose was 3.5 × 107/kg, 60% were 4/6 HLA mismatched. Sustained donor engraftment was seen in 88% (95% CI: 83-97) at a median of 24 days. Complete donor chimerism was derived from one unit by day 60 in all but 4 patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
